Loading
Camizestrant / Breast Cancer, Early Breast Cancer / Letrozole · Phase 3 Trial
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registration comparing camizestrant to standard endocrine therapy (tamoxifen or aromatase inhibitors) in ER+/HER2− early breast cancer patients who have completed at least 2 years of prior adjuvant endocrine therapy. No results are reported in this registry record; the study is actively recruiting and remains ongoing.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Breast Cancer, Early Breast Cancer; age from 18 Years; to 130 Years. Intervention: Arm B: camizestrant. Compared with: Arm A: standard endocrine therapy of investigator´s choice — Active Comparator. n = 4,300. 709 sites across 39 countries.
This is a Phase 3 trial registration comparing camizestrant to standard endocrine therapy (tamoxifen or aromatase inhibitors) in ER+/HER2− early breast cancer patients who have completed at least 2 years of prior adjuvant endocrine therapy. No results are reported in this registry record; the study is actively recruiting and remains ongoing.
This is a registry record with no results reported; efficacy, safety, and tolerability data are not yet available.
The source did not state who this applies to in practice.
This is an active Phase 3 trial registration with no reported results; the study design and primary endpoint are specified but outcome data are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05774951). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 4300 participants (ESTIMATED). Conditions: Breast Cancer, Early Breast Cancer. Interventions: DRUG: Camizestrant; DRUG: Tamoxifen; DRUG: Anastrozole; DRUG: Letrozole; DRUG: Exemestane. Primary outcome measures: Invasive breast cancer-free survival (IBCFS) , Up to 10 years. Brief summary: This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.